Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Kshirsagar, Abhijit V ^a   Freburger, Janet K ^b   Ellis, Alan R ^b   Wang, Lily ^b   Winkelmayer, Wolfgang C ^c   Brookhart, M Alan ^b,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

ADULT; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; SUPPLEMENTATION; TREATMENT DURATION; UNITED STATES;

ADMINISTRATION, INTRAVENOUS; AGED; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; IRON; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 84891434596     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078930     Document Type: Article

References (35)

1. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC et al. (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084. doi: 10.1056/NEJMoa062276. PubMed: 17108342.
2. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S et al. (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098. doi:10.1056/NEJMoa065485. PubMed: 17108343.
3. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D et al. (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032. doi:10.1056/NEJMoa0907845. PubMed: 19880844.
4. Centers for Medicare & Medicaid Services (2011) Medicare Program; End-Stage Renal Disease Prospective Payment System and Quality Incentive Program; Ambulance Fee Schedule; Durable Medical Equipment; and Competitive Acquisition of Certain Durable Medical Equipment, Prosthetics, Orthotics and Supplies; Final Rule. Fed Regist 76: 218. Available: http://www.gpo.gov/fdsys/ pkg/FR-2011-11-10/pdf/2011-28606.pdf. Accessed 3 March 2013.
5. Freburger JK, Ng LJ, Bradbury BD, Kshirsagar AV, Brookhart MA (2012) Changing patterns of anemia management in US hemodialysis patients. Am J Med 125: 906-914 e909 doi:10.1016/j.amjmed.2012.03.011. PubMed: 22938926.
6. Thakuria M, Ofsthun NJ, Mullon C, Diaz-Buxo JA (2011) Anemia management in patients receiving chronic hemodialysis. Semin Dial 24: 597-602. doi:10.1111/j.1525-139X.2011.00975.x. PubMed: 21999745.
7. Yong K, Kairaitis L (2010) Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort. Nephrology (Carlton) 15: 288-293. doi:10.1111/j.1440-1797.2009.01184.x.
8. Brewster UC (2006) Intravenous iron therapy in end-stage renal disease. Semin Dial 19: 285-290. doi:10.1111/j.1525-139X.2006.00174.x. PubMed: 16893405.
9. Halliwell B, Gutteridge JM (1984) Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 219: 1-14. PubMed: 6326753.
10. Martin-Malo A, Merino A, Carracedo J, Alvarez-Lara MA, Ojeda R et al. (2011) Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant, 27: 2465-71. PubMed: 22207322.
11. Sevanian A, Hochstein P (1985) Mechanisms and consequences of lipid peroxidation in biological systems. Annu Rev Nutr 5: 365-390. doi: 10.1146/annurev.nu.05.070185.002053. PubMed: 2992549.
12. Berliner JA, Heinecke JW (1996) The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 20: 707-727. doi: 10.1016/0891-5849(95)02173- 6. PubMed: 8721615.
13. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM et al. (2009) Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302: 1782-1789. doi:10.1001/jama.2009.1488. PubMed: 19861670.
14. (2011) Researcher's Guide to the USRDS Database: 2010 ADR Edition. Bethesda, MD: National Institutes of Health, NIDDK.
15. Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36: 8-27. doi: 10.1097/00005650- 199801000-00004. PubMed: 9431328.
16. Lin DY, Ying Z (1994) Semiparametric analysis of the additive risk model. Biometrika 81: 61-71. doi:10.1093/biomet/81.1.61.
17. Akizawa T, Pisoni RL, Akiba T, Saito A, Fukuhara S et al. (2008) Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS. Nephrol Dial Transplant 23: 3643-3653. doi:10.1093/ndt/gfn346. PubMed: 18577535.
18. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y et al. (2004) Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44: 94-111. doi:10.1053/j.ajkd.2004.03.023. PubMed: 15211443.
19. Biemond P, Swaak AJ, van Eijk HG, Koster JF (1988) Superoxide dependent iron release from ferritin in inflammatory diseases. Free Radic Biol Med 4: 185-198. doi:10.1016/0891-5849(88)90026-3. PubMed: 2833431.
20. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM (2002) The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538. doi:10.1046/j.1523-1755.2002.00600.x. PubMed: 12371953.
21. Zanen AL, Adriaansen HJ, van Bommel EF, Posthuma R, de Jong Th GM (1996) 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients. Nephrol Dial Transplant 11: 820-824. doi:10.1093/oxfordjournals.ndt.a027405. PubMed: 8671901.
22. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP et al. (2002) Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212-2217. doi:10.1161/01.CIR. 0000035250.66458.67. PubMed: 12390950.
23. Reis KA, Guz G, Ozdemir H, Erten Y, Atalay V et al. (2005) Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J 46: 255-264. doi:10.1536/ihj.46.255. PubMed: 15876809.
24. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B et al. (2004) Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15: 1623-1632. doi:10.1097/01.ASN. 0000128009.69594.BE. PubMed: 15153574.
25. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG (2005) Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16: 3070-3080. doi:10.1681/ASN.2005040423. PubMed: 16033854.
26. Robins JM, Hernán MA, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550-560. doi: 10.1097/00001648-200009000-00011. PubMed: 10955408.
27. Center for Medicare & Medicaid Services (2012) Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Bad Debt Reductions for All Medicare Providers; Proposed Rule 28. Fed Regist 77: 133. Available: http://www.gpo.gov/fdsys/pkg/FR-2012-07-11/pdf/2012-16566. pdf. Accessed 4 March 2013
28. FDA (2011) Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease. Retrieved onpublished at whilst December year 1111 from http://www.fda.gov/drugs/drugsafety/ucm259639. Accessed 4 March 2013.
29. Hoen B, Paul-Dauphin A, Hestin D, Kessler M (1998) EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9: 869-876. PubMed: 9596085.
30. Parkkinen J, von Bonsdorff L, Peltonen S, Grönhagen-Riska C, Rosenlöf K (2000) Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15: 1827-1834. doi: 10.1093/ndt/15.11.1827. PubMed: 11071973.
31. Fishbane S (1999) Review of issues relating to iron and infection. Am J Kidney Dis 34: S47-S52. doi:10.1053/ajkd.1999.v34.aajkd0344b0047. PubMed: 10516376.
32. Singh N, Agarwal AK (2012) Pumping iron: revisiting risks, benefits and strategies in treatment of iron deficiency in end-stage renal disease. Clin Nephrol 77: 188-194. doi:10.5414/CN107266. PubMed: 22377249.
33. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC et al. (2013) The Comparative Short-term Effectiveness of Iron Dosing and Formulations in US Hemodialysis Patients. In press: Am J Med. PubMed: 23597800.
34. Spiegel DM, Chertow GM (2009) Lost without directions: lessons from the anemia debate and the drive study. Clin J Am Soc Nephrol 4: 1009-1010. doi:10.2215/CJN.00270109. PubMed: 19357246.
35. Vaziri ND (2012) Epidemic of iron overload in dialysis population caused by intravenous iron products: a plea for moderation. Am J Med 125: 951-952. doi:10.1016/j.amjmed.2012.02.009. PubMed: 22795817.